Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.71 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 3/20 | 0.65 |
| ▸ | INSR | P06213 | 3/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.65 |
| ▸ | CDK2 | P24941 | 3/20 | 0.65 |
| ▸ | PLK1 | P53350 | 3/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510931 | 0.90 | EGFR (0.75) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL2505296 | 0.90 | EGFR (0.77) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL14509726 | 0.90 | EGFR (0.75) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL9910667 | 0.90 | EGFR (0.67) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL27858408 | 0.90 | EGFR (0.64) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL12691367 | 0.89 | EGFR (0.76) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL29693649 | 0.89 | EGFR (0.73) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL9973598 | 0.89 | EGFR (0.73) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL14878664 | 0.89 | EGFR (0.79) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL141514 | 0.89 | EGFR (0.73) | EGFRERBB2GAKERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | claimed |
| JP-2008525522-A | — | — | 2008-07-17 | — | — | JP | claimed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | claimed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9676791-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9527865-B2 | — | — | 2016-12-27 | — | — | US | disclosed |
| US-9102629-B2 | Polymorphic forms of 4-phenylamine quinazoline derivative, the preparation method and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2015-08-11 | — | — | US | disclosed |
| US-20150133476-A1 | Polymorphic forms of 4-phenylamino quinazoline derivative, the preparation method and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| US-8937079-B2 | Polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2015-01-20 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| EP-1660090-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005016346-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133476-A1 | Polymorphic forms of 4-phenylamino quinazoline derivative, the preparation method and uses thereof | CYP2D6, ABCG2, CYP3A43 | EGFR 4165/4885ERBB2 3568/4885GAK 1795/4885 |
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, FLT3, RET | EGFR 4/4885ERBB2 7/4885GAK 706/4885 |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1400/4885ERBB2 1693/4885GAK 89/4885 |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | EGFR 4/4885ERBB2 2/4885GAK 341/4885 |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885ERBB2 2/4885GAK 245/4885 |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 6/4885ERBB2 2/4885GAK 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.